Kanjinti and Mvasi Make ‘Solid Start’ In US

Amgen’s Global Biosimilars Annualizing At Around $700m

 
• By Aidan Fry
  
Sprinting
Amgen says its Kanjinti and Mvasi biosimilars have made a solid start in the US • Source: Shutterstock

More from Biosimilars

More from Products